Adefovir causes increased bone loss in patients by binding to LCN2, while CXCL8, a specific target of tenofovir, interferes with the expression of CXLC8, and patients ultimately experience adverse events of osteoporosis (67). Here, CXCL8 is linked to osteoporosis.